Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lung cancer
#NCT05384626
#2024-514266-39-00
Cohortes G et H (Cohortes DDI)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
#NCT05384626
#2024-514266-39-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
AKT
ATM
BRAF
BRCA 1/2
CDK12
CHEK 1/2
ESR
FGFR
HER2
HOXB13
KRAS G12C
KRAS non G12C
MET
MSI/dMMR
NRAS
NTRK-1/2/3
PALB2
PIK3CA
PTEN
RET
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT05384626
#2024-514266-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 1 (Escalade de dose et Backfilling)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 1 (Escalade de dose)
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 2
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 6
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohortes 3 et 5
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 1 et 4
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
BioNTech SE